The “Growth Opportunities in Global Diabetes and Obesity Therapeutics, 2024-2028” report has been recently included in ResearchAndMarkets.com’s offerings.
This comprehensive study aims to identify key growth opportunities driving the diabesity market in the coming years. It focuses on emerging business models that enable industry stakeholders to expand their geographic coverage and address challenges in patient access.
Globally, there has been a significant rise in metabolic diseases like type 2 diabetes and obesity, exacerbated by the COVID-19 pandemic. Obesity, a major precursor to diabetes, contributes substantially to its risk. This has escalated healthcare costs and heightened demand for combination treatments targeting both conditions (diabesity).
Current therapies for obesity often have limited efficacy and safety profiles, alongside challenges in disease management variability. Consequently, there is growing demand for newer drug classes such as GLP-1 receptor agonists, which offer enhanced glycemic control and weight loss, improving clinical outcomes. This surge in demand is prompting increased global research and development efforts among market participants. Strategies to enhance supply, affordability, and patient access, while curbing off-label use, are driving the adoption of direct-to-consumer and hybrid care models.
Life sciences companies are expected to intensify efforts to develop pharmacological therapies that are safer, more effective, and offer sustained weight loss without muscle loss. Innovations in drug delivery and benefits across the cardiometabolic spectrum will be crucial competitive differentiators.
Strategic research collaborations are anticipated to expedite the development of next-generation medicines and novel drug classes, as well as non-traditional healthcare solutions. A patient-centric approach combining pharmacotherapy with nutrition, behavioral, and lifestyle interventions is poised to shape future treatment strategies.
Moreover, precision medicine (PM) advancements are set to elevate disease management standards over the next five years, supported by initiatives like the collaboration between the Novo Nordisk Foundation Centre for Genomic Mechanism of Diseases and the Broad Institute of Cambridge.
The report also examines key market drivers and constraints, highlighting leading participants driving innovation in each indication. It covers significant M&A and partnership activities influencing market dynamics, as well as current and future trends shaping the industry from 2021 to 2028.
